2021. Restricted Mean Survival Time and Cure-Rate Modeling in Estimating Relapse-Free Survival Benefit With Adjuvant Dabrafenib + Trametinib Treatment in Melanoma. SKIN The Journal of Cutaneous Medicine. 5, 1 (Jan. 2021), s2. DOI:https://doi.org/10.25251/skin.5.supp.2.